Viewing Study NCT04719221



Ignite Creation Date: 2024-05-06 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 1:54 PM
Study NCT ID: NCT04719221
Status: RECRUITING
Last Update Posted: 2023-10-05
First Post: 2021-01-12

Brief Title: Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
Sponsor: Korea University Anam Hospital
Organization: Korea University Anam Hospital

Study Overview

Official Title: A Single-center Randomized Parallel-group Open-label Pilot Study to Evaluate the Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
Status: RECRUITING
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aimed to investigate the impact of intensive cholesterol-lowering therapy including evolocumab drug treatment for high-risk plaques Vulnerable plaques with a high probability of developing acute coronary syndrome The purpose of this study is to determine the effect of the change in the Lipid core burden index and compare the rate of cardiac events over 12 months following cholesterol therapy
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None